Therapeutic Hotline: Cysteinyl leukotriene receptor antagonist montelukast in the treatment of atopic dermatitis.
Leukotrienes are potent proinflammatory mediators derived from arachidonic acid through the 5-lipoxygenase pathway. Experimental data suggest a role for cysteinyl leukotrienes in the pathogenesis of atopy giving a rationale for its use in asthma, allergic rhinitis, and chronic urticaria management. A few clinical observations and small trials suggest that montelukast may be used in an adjunctive manner as an effective therapeutic option for all age categories affected by moderate-to-severe atopic dermatitis. Our own observations proved that montelukast as a prospective corticosteroid-sparing option in the complex therapeutic strategy of corticosteroid-dependent atopic dermatitis patients, even in the severe erythrodermic cases.
Broshtilova
Valentina
V
Department of Dermatology and Venereology, Medical University, Sofia, Bulgaria.
Gantcheva
Mary
M
D000085:Acetates / Q000627:therapeutic use*; D000328:Adult; D001249:Asthma / Q000188:drug therapy; D003521:Cyclopropanes; D003876:Dermatitis, Atopic / Q000188:drug therapy*; D004802:Eosinophilia / Q000188:drug therapy; D005122:Exudates and Transudates / Q000187:drug effects; D005260:Female; D006801:Humans; D007073:Immunoglobulin E / Q000097:blood; D020024:Leukotriene Antagonists / Q000627:therapeutic use*; D008297:Male; D008775:Methylprednisolone / Q000627:therapeutic use; D011804:Quinolines / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D018077:Receptors, Leukotriene / Q000378:metabolism; D012220:Rhinitis / Q000188:drug therapy; D013440:Sulfides; D016896:Treatment Outcome; D055815:Young Adult
D000085:Acetates; D003521:Cyclopropanes; D020024:Leukotriene Antagonists; D011804:Quinolines; D018077:Receptors, Leukotriene; D013440:Sulfides; D007073:Immunoglobulin E; C083169:leukotriene D4 receptor; C093875:montelukast; D008775:Methylprednisolone